A phase 2, randomized, double-blind, placebo-controlled study to evaluate a single intravenous dose of motavizumab (MEDI-524), a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), for the treatment of children hospitalized with RSV illness.

Trial Profile

A phase 2, randomized, double-blind, placebo-controlled study to evaluate a single intravenous dose of motavizumab (MEDI-524), a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), for the treatment of children hospitalized with RSV illness.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2013

At a glance

  • Drugs Motavizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2013 Results published in the Pediatric Infectious Disease Journal.
    • 24 May 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 24 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top